A retrospective analysis was undertaken of patients (n = 193) with renal insufficiency (creatinine clearance [CrCl] < 60 mL/min) from a phase III trial comparing bortezomib ± pegylated liposomal doxorubicin (PLD) in relapsed/refractory myeloma (n = 646). The response rate (49% vs. 42%) and median time to disease progression (331 days vs. 199 days) were comparable or slightly better for patients with renal insufficiency treated with PLD/bortezomib compared with patients treated with bortezomib alone. There was a steady, clinically meaningful improvement in renal function for patients with renal insufficiency in both treatment arms. However, patients with impaired renal function were at a slightly increased risk of a drug-related serious adverse event (28% vs. 19% for CrCl < 60 and ≥ 60 mL/min, respectively).

, ,
doi.org/10.3816/CLM.2008.n.051, hdl.handle.net/1765/32506
Clinical Lymphoma and Myeloma
Erasmus MC: University Medical Center Rotterdam

Bladé, J., Sonneveld, P., San Miguel, J. F., Sutherland, H., Hajek, R., Nagler, A., … Orlowski, R. (2008). Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: Efficacy and safety in patients with renal function impairment. Clinical Lymphoma and Myeloma, 8(6), 352–355. doi:10.3816/CLM.2008.n.051